News & Events

May 2, 2022
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Stephen Mullennix as Chief Financial Officer (CFO). Mr. Mullennix brings more than 20 years of financial and operational expertise in the biotechnology and private equity sectors to Plexium, with a strong background in developing and executing corporate and financial growth strategies.
April 27, 2022
Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions. This collaboration combines AbbVie’s extensive neuroscience capabilities with Plexium’s comprehensive TPD platform that enables the discovery of novel therapies toward historically challenging drug targets.
April 6, 2022
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced that Plexium President & CEO, Percival Barretto-Ko, will participate at the Longwood Healthcare Leaders Spring MIT webconference in a panel titled Cultivating An Ecosystem Of Partners on Wednesday, May 4, 2022. The conference is being held virtually May 4-5, 2022.
February 22, 2022
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the completion of an oversubscribed $102M financing, led by BVF Partners, L.P. and TCG X, with participation from new investors Softbank Vision Fund 2, RA Capital Management, Surveyor Capital (a Citadel company), and Pappas Capital. Existing investors The Column Group, DCVC Bio, Pivotal bioVenture Partners, Lux Capital, M Ventures, CRV and Neotribe Ventures also participated in the round.
February 2, 2022
Collaboration Combines Plexium’s Novel Technology Platform With Amgen’s Early Discovery Expertise to Identify and Develop new Therapeutic Agents in Cancer and Other Serious Diseases THOUSAND OAKS and San Diego, Calif. (Feb. 03, 2022) – Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted […]
November 3, 2021
San Diego, Calif., November 4, 2021 – Plexium Inc., (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer and a member of the Board of Directors. Mr. Barretto-Ko joins Plexium following a sixteen-year tenure with Astellas Pharma Inc., a […]
October 7, 2021
SAN DIEGO, Oct. 5, 2021 – Plexium Inc., (Plexium), a biotech company focused on discovering and developing protein degrading therapeutics directed towards historically challenging drug targets, today announced that company management will present and host one-on-one meetings at the Solebury Trout/BMO Fall Private Company Showcase 2021. The company will present on Thursday, October 14th, 2021 at […]
January 20, 2021
Company also announces appointment of biotech veteran Mike Grey as Chairman of the Board SAN DIEGO, October 19, 2020 – Plexium Inc., a biotech company focused on discovering and developing protein degrading therapeutics directed towards historically challenging drug targets, today announced the completion of a $35M financing, led by Lux Capital and Pivotal BioVentures, with […]
October 16, 2019
Funds will help advance Plexium’s DELPhe platform to discover novel E3 ligase-modulating therapeutics to treat cancer and neurodegenerative diseases SAN DIEGO, October 17, 2019 – Plexium today announced the launch of the company with the closing of a $28 million Series A financing. The financing was led by DCVC Bio and The Column Group, with […]
October 9, 2019
Plexium CEO Swamy Vijayan to present at the North American Protein Degradation Congress in San Diego, CA on February 4-5, 2020.